Literature DB >> 6352661

A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia.

L A Mandell, L E Nicolle, A R Ronald, R Duperval, H G Robson, R Feld, J Vincelette, I Fong.   

Abstract

A multicentre prospective randomized control trial was done to compare the efficacy and toxicity of ceftazidime with that of cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. The results for 50 patients are reported in this paper; 24 in the ceftazidime group and 26 in the cefazolin/tobramycin group. Measurements of clinical response show no differences between the two groups: the same is true for bacteriological response. Minimal toxicity was seen with both treatment groups. The results support the use of ceftazidime as single-drug treatment of hospitalized patients with pneumonia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352661     DOI: 10.1093/jac/12.suppl_a.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Systemic antibiotic treatment of nosocomial pneumonia.

Authors:  K E Unertl; F P Lenhart; H Forst; K Peter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

2.  Modeling the response of pneumonia to antimicrobial therapy.

Authors:  J M Hyatt; A B Luzier; A Forrest; C H Ballow; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.

Authors:  D A Conrad; R K Scribner; A H Weber; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 4.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  [Ceftazidime versus cefotaxime in the therapy of severe infections in intensive care patients].

Authors:  E Müller; J Heinkelein
Journal:  Infection       Date:  1987       Impact factor: 3.553

6.  [Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients].

Authors:  S Kljucar; M Heimesaat; E von Pritzbuer; K Olms
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 7.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

Review 8.  Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy.

Authors:  F M LaForce
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

Review 9.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 10.  Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.

Authors:  R G Masterton; A Galloway; G French; M Street; J Armstrong; E Brown; J Cleverley; P Dilworth; C Fry; A D Gascoigne; Alan Knox; Dilip Nathwani; Robert Spencer; Mark Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-04-29       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.